Skip to main content

Table 1 Patient characteristics, history of prostate cancer and outcome from lymphadenectomies from 23 patients undergoing lymphadenectomy

From: Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET/CT-positive nodal metastatic prostate cancer

ParametersValues
iPSA at primary therapy (ng/ml)
 Mean ± SD/median/range10.79 ± 7.5/8.8/3.37–37.0
Primary therapy, n
 Radical prostatectomy21/23 (91.3%)
 Radiotherapy2/23 (8.7%)
Gleason score, n
 7a4 (17%)
 7b7 (31%)
 85 (22%)
 97 (30%)
111In-PSMA-guided LA overall, n
 Primary2/23 (8.7%)
 Salvage lymph node dissection21/23 (91.3%)
Age at lymphadenectomy (years)
 Mean ± SD/median/range67.5 ± 6.6/67/52–78
PSA at 111In-PSMA-guided LA (ng/ml)
 Mean ± SD/median/range7.9 ± 12.9/1.8/0.03–56.2
Time between PET/CT and 111In-PSMA-guided LA (months)
 Mean ± SD/median/range3.2 ± 1.6/3.0/1.0–8.0
Time between primary therapy and 111In-PSMA-guided LA (years) (n = 21)
 Mean ± SD/median/range4.9 ± 3.7/4.4/1.5–13.7
Histological outcome for 23 patients, n
 LA with positive histology21/23 (91.3%)
 LA with negative histology2/23 (8.7%)
Topography of 111In-PSMA-guided LA in 23 patients, n
 Pelvic right and left13/23 (57%)
 Pelvic left only2/23 (9%)
 Pelvic right only1/23 (4%)
 Pelvic right and left and retroperitoneal7/23 (30%)
Topography of subregions with confirmed PCa, n
 Pelvic left, n38/275 (37%)
 Pelvic right, n41/275 (40%)
 Retroperitoneal24/275 (23%)
Histological outcome for 275 subregions with 275 samples, n
 Subregions/samples with LNM104/275 (37.5%)
 Subregions/samples without LNM171/275 (62.5%)
 Subregions/samples with additional non-nodal PCa-tissue7/104 (5.8%)
Number of LN removed (n)
 Overall864
 Per patient (mean ± SD/median/range)37.6 ± 17.2/38.0/2.0–82.0
Number of LNM removed (n)
 Overall197
 Per patient (mean ± SD/median/range)8.6 ± 14.9/4.0/0.0–71.0
LNM fraction per patient (LNM×100/LN = %)
 Mean ± SD/median/range20.9 ± 24.4/12.5/0.0–87.1
  1. LNM lymph node metastases, LN lymph node, PSA prostate-specific antigen, LA lymphadenectomy